Influenza Vaccine: a Review on Current Scenario and Future Prospects

Overview

Journal J Genet Eng Biotechnol

Specialty Biotechnology

Date 2023 Nov 29

PMID 38030859

Authors

Dipanshi Gupta

Sumedha Mohan

Affiliations

Soon will be listed here.

Abstract

Vaccination is a crucial tool in preventing influenza, but it requires annual updates in vaccine composition due to the ever-changing nature of the flu virus. While healthcare and economic burdens have reduced, the virus remains a challenge. Research conducted over the past decade has revealed pathways for improvement through both basic and clinical studies. Viral surveillance plays a vital role in the better selection of candidate viruses for vaccines and the early detection of drug-resistant strains.This page offers a description of future vaccine developments and an overview of current vaccine options. In the coming years, we anticipate significant changes in vaccine production, moving away from traditional egg-based methods towards innovative technologies such as DNA and RNA vaccines. These newer approaches offer significant advantages over traditional egg-based and cell culture-based influenza vaccine manufacturing.

Citing Articles

Insights into IAV Replication and Lipid Metabolism in Suspension-Adapted MDCK-STAT1-KO Cells.

Ye Q, Yao H, Xiao Z, Zhao L, Tan W Vaccines (Basel). 2025; 13(2).

PMID: 40006653 PMC: 11860519. DOI: 10.3390/vaccines13020106.

A vaccine platform targeting lung-resident memory CD4 T-cells provides protection against heterosubtypic influenza infections in mice and ferrets.

Ko K, Bae H, Park J, Lee J, Park S, Heo J Nat Commun. 2024; 15(1):10368.

PMID: 39609429 PMC: 11604757. DOI: 10.1038/s41467-024-54620-4.

TRIM46 accelerates H1N1 influenza virus-induced ferroptosis and inflammatory response by regulating SLC7A11 ubiquitination.

Zhou C, Bao G, Chen Y J Bioenerg Biomembr. 2024; 56(6):631-643.

PMID: 39531094 DOI: 10.1007/s10863-024-10043-w.

Advancements in LAMP-Based Diagnostics: Emerging Techniques and Applications in Viral Detection with a Focus on Herpesviruses in Transplant Patient Management.

Gomes Torres A, Mathias C, Baal S, Kohler A, Cunha M, Blanes L Int J Mol Sci. 2024; 25(21).

PMID: 39519059 PMC: 11546353. DOI: 10.3390/ijms252111506.

Drug resistance and possible therapeutic options against influenza A virus infection over past years.

Asif Raza M, Ashraf M Arch Microbiol. 2024; 206(12):458.

PMID: 39499323 DOI: 10.1007/s00203-024-04181-3.

References

Montomoli E, Torelli A, Manini I, Gianchecchi E . Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults. Vaccines (Basel). 2018; 6(1). PMC: 5874655. DOI: 10.3390/vaccines6010014. View

Kheyrolahzadeh K, Tohidkia M, Tarighatnia A, Shahabi P, Nader N, Aghanejad A . Theranostic chimeric antigen receptor (CAR)-T cells: Insight into recent trends and challenges in solid tumors. Life Sci. 2023; 328:121917. DOI: 10.1016/j.lfs.2023.121917. View

Corti D, Voss J, Gamblin S, Codoni G, Macagno A, Jarrossay D . A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011; 333(6044):850-6. DOI: 10.1126/science.1205669. View

Zhao Q, Li S, Yu H, Xia N, Modis Y . Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol. 2013; 31(11):654-63. DOI: 10.1016/j.tibtech.2013.09.002. View

Houser K, Chen G, Carter C, Crank M, Nguyen T, Burgos Florez M . Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat Med. 2022; 28(2):383-391. PMC: 10588819. DOI: 10.1038/s41591-021-01660-8. View

Kim H, Webster R, Webby R . Influenza Virus: Dealing with a Drifting and Shifting Pathogen. Viral Immunol. 2018; 31(2):174-183. DOI: 10.1089/vim.2017.0141. View

Asha K, Kumar B . Emerging Influenza D Virus Threat: What We Know so Far!. J Clin Med. 2019; 8(2). PMC: 6406440. DOI: 10.3390/jcm8020192. View

Young B, Sadarangani S, Jiang L, Wilder-Smith A, Chen M . Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies. J Infect Dis. 2017; 217(5):731-741. DOI: 10.1093/infdis/jix632. View

Yamayoshi S, Kawaoka Y . Current and future influenza vaccines. Nat Med. 2019; 25(2):212-220. DOI: 10.1038/s41591-018-0340-z. View

10.

Muszkat M, Greenbaum E, Ben-Yehuda A, Oster M, Yeul E, Heimann S . Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine. 2003; 21(11-12):1180-6. DOI: 10.1016/s0264-410x(02)00481-4. View

11.

Sharma S . The role of nanomedicine in COVID-19 therapeutics. Nanomedicine (Lond). 2022; 17(3):133-136. PMC: 8751627. DOI: 10.2217/nnm-2021-0358. View

12.

Pillet S, Aubin E, Trepanier S, Bussiere D, Dargis M, Poulin J . A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol. 2016; 168:72-87. DOI: 10.1016/j.clim.2016.03.008. View

13.

Krishnan A, Dar L, Amarchand R, Prabhakaran A, Kumar R, Rajkumar P . Cohort profile: Indian Network of Population-Based Surveillance Platforms for Influenza and Other Respiratory Viruses among the Elderly (INSPIRE). BMJ Open. 2021; 11(10):e052473. PMC: 8499317. DOI: 10.1136/bmjopen-2021-052473. View

14.

Bezbaruah R, Chavda V, Nongrang L, Alom S, Deka K, Kalita T . Nanoparticle-Based Delivery Systems for Vaccines. Vaccines (Basel). 2022; 10(11). PMC: 9694785. DOI: 10.3390/vaccines10111946. View

15.

Plotkin S, Plotkin S . The development of vaccines: how the past led to the future. Nat Rev Microbiol. 2011; 9(12):889-93. DOI: 10.1038/nrmicro2668. View

16.

Nachbagauer R, Feser J, Naficy A, Bernstein D, Guptill J, Walter E . A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2020; 27(1):106-114. DOI: 10.1038/s41591-020-1118-7. View

17.

Al-Halifa S, Gauthier L, Arpin D, Bourgault S, Archambault D . Nanoparticle-Based Vaccines Against Respiratory Viruses. Front Immunol. 2019; 10:22. PMC: 6353795. DOI: 10.3389/fimmu.2019.00022. View

18.

Xie H, Wan X, Ye Z, Plant E, Zhao Y, Xu Y . H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps. Sci Rep. 2015; 5:15279. PMC: 4607887. DOI: 10.1038/srep15279. View

19.

Xue W, Li T, Gu Y, Li S, Xia N . Molecular engineering tools for the development of vaccines against infectious diseases: current status and future directions. Expert Rev Vaccines. 2023; 22(1):563-578. DOI: 10.1080/14760584.2023.2227699. View

20.

Robertson C, DiazGranados C, Decker M, Chit A, Mercer M, Greenberg D . Fluzone® High-Dose Influenza Vaccine. Expert Rev Vaccines. 2016; 15(12):1495-1505. DOI: 10.1080/14760584.2016.1254044. View